Harold Brooks, MD
Ophthalmology · Tallahassee, FLNPI 1831157890
Payments from drug & device makers
What this record shows
The money is spread across several categories — ownership interests (55.3%), other and food and beverage — rather than concentrated in one kind of arrangement. US Retina LLC accounts for 99.5% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2021 at $452,070 and has fallen 99.9% since, to $581 in 2025. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 117 payments — averaging $5839.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$680K
- Genentech, Inc.$1K
- Genentech USA, Inc.$762
- AbbVie$501
- Regeneron Healthcare Solutions, Inc.$231
- Apellis Pharmaceuticals, Inc.$149
- plus $503 from 8 others
Across 178 payments — averaging $15,703 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$2.6M
- Regeneron$189K
- F. Hoffmann-la Roche AG$7K
- Novartis$6K
- Aerie Pharmaceuticals, Inc.$4K
What the payments were for
- Travel & lodging$9260%
- Food & beverage$2,5720%
- Ownership interest$377,61355%
- Other$302,15644%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 11 | $679,769 |
| Genentech, Inc. | 7 | $1,350 |
| Genentech USA, Inc. | 35 | $762 |
| AbbVie(2 entities) | 23 | $501 |
| Regeneron Healthcare Solutions, Inc. | 11 | $231 |
| Apellis Pharmaceuticals, Inc. | 6 | $149 |
| Astellas Pharma US Inc | 4 | $91 |
| Novartis | 6 | $90 |
| Biogen | 4 | $87 |
| Bausch & Lomb Americas Inc. | 4 | $82 |
| Sandoz | 2 | $69 |
| Mallinckrodt Hospital Products Inc. | 2 | $39 |
| Cook Medical LLC | 1 | $32 |
| Coherus Oncology, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered Product$1,238
How this compares
$683,266 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 226 | $11,650 |
| Difluprednate | 53 | $5,276 |
| Alphagan PBrimonidine Tartrate | 11 | $2,791 |
| Atropine Sulfate | 37 | $1,411 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 134 | $1,107 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 60 | $613 |
| MoxifloxacinMoxifloxacin Hcl | 25 | $581 |
| ErythromycinErythromycin Base | 26 | $251 |
| Latanoprost | 13 | $134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieAlphagan P | $501 | $2,79111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Tallahassee
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Robert WeinstockLargo$605K
- William TrattlerMiami$579K
- Farrell TysonCape Coral$579K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.